Skip to main content
  • Global
  • US
  • en
  • de
  • Jobs
  • Patients
  • Healthcare Professionals
  • Partners
  • Investors
  • Media

Search

Home

Flyout

  • About us

    About us

    MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines.

    Learn more
    • Company
    • Leadership
    • History
    • Responsibility
    alt
  • Our Pipeline

    Our Pipeline

    MorphoSys has a broad mid- to late-stage pipeline with a focus on hematology and oncology.

    Learn more
    • Our Pipeline
    • Tafasitamab
    • Pelabresib
    • CPI-0209
    • Felzartamab
    • Clinical Trials
    Pipeline
  • Our Medicines
  • Our Science

    Our Science

    MorphoSys applies state-of-the-art research capabilities and expertise in novel discovery platforms to develop new compounds.

    Learn more
    • Value of Science
    • Technologies
    Science
  • Careers
  • Global
  • US
  • en
  • de
  • Jobs
  • Patients
  • Healthcare Professionals
  • Partners
  • Investors
  • Media
Our Medicines
Our Medicines

Our Medicines

We strive to deliver breakthrough medicines to people living with cancer.

  1. Home
  2. Our Medicines

Our Approved Medicines

Monjuvi
Monjuvi

Monjuvi® (tafasitamab-cxix)

Learn More (For U.S. Residents Only)

Footer-first-column

  • About Us
  • Leadership
  • Careers

Footer-second-column

  • Pipeline
  • Medicines
  • Clinical Studies

Footer-third-column

  • Partners
  • Investors
  • Media

Footer-fifth-column

  • Imprint
  • Terms and Conditions
  • Privacy Policy
  • Contact Us
© 2022 MorphoSys AG
CORP-GL-00127

You are now leaving the MorphoSys.com website. This link will take you to a different website. You are solely responsible for your interactions with that website.

Do you wish to proceed ?

  • Yes
  • No
  • I am a U.S. Healthcare Professional
  • I am a U.S. Patient or Caregiver